← Home / Aligos Therapeutics, Inc. (ALGS)
Stock Analysis
Aligos Therapeutics, Inc. (ALGS)
ALGS
ALGS · Market data
4.23 -2.08%
Track ALGS in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when ALGS price is:
52W Range Position
2%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-02 14:42 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Strong / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
5.40
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
JUN
26
●
Management / Board
MEDIUM
ALGS board and management update
On June 25, 2026, Aligos Therapeutics, Inc.
8-K Filing • SEC EDGAR
JUN
26
●
Shareholder Vote
MEDIUM
ALGS shareholder vote update
At the Annual Meeting, the Company’s stockholders voted on five proposals, each of which is described in more detail in the Proxy Statement.
8-K Filing • SEC EDGAR
MAY
7
●
Financial Results
HIGH
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
(Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the first quarter 2026.
8-K Filing • SEC EDGAR
What's Driving ALGS?
📈 Technical recovery is improving
Momentum is Neutral. Watch 5.40 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
32.4
Price Chart
ALGS — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$26.2M
Company size
EV
$-3.7M
Debt-adjusted value
P/E
-1.1
Not meaningful
P/S
12.0
Premium
P/B
0.8
Low book multiple
EV/Sales
-1.7
Not meaningful
EV/EBIT
0.0
Low multiple
P/FCF
-0.3
Not meaningful
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Strong
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Manageable
💵 Revenue
2.83M
↗ Strong
📈 Net Income
-23.04M
↘ Negative
🧮 EPS (Basic)
-2.21
↘ Negative
Aligos Therapeutics, Inc.
Related Opportunities